Abstract
Dibromomannitol, a halogenated polyalcohol, used orally was found to be effective in the treatment of chronic myelogenous leukemia. In 9 patients with chronic myelogenous leukemia, dibromomannitol was administered in a single daily dose of 250 mg for remission induction, this later decreasing to a dose ranging from 50 mg to 250 mg q. d. or q. o. d. for remission maintenance. The dose was adjusted according to peripheral blood counts while in remission. of/4 courses of treatment in them, symptomatic and hematologic control was achieved in/3 courses (93%) by 9 weeks (median). Regardless of previous treatment, high resoonce rate to this drug was obtained, suggesting the efficacy of dibromomannitol in patients resistent to other conventional cytotoxic drug.
The myelosupression was, within the dose range employed, relatively granuloytespecific. Side effect was minimal, such as mild gastrointestinal disturbance.
